-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, supported by a series of favorable policies, the domestic pharmaceutical industry has developed rapidly, and the transformation and upgrading have also begun to accelerate
.
Data shows that in recent years, the innovation and R&D investment of local pharmaceutical companies has continued to rise
.
Among them, the R&D investment of large-scale enterprises has an average annual growth rate of about 8%, and the R&D expenses of listed companies will account for more than 6% of sales revenue in 2020
.
In addition, the R&D investment of innovative drug industry chain companies in the third quarter of 2021 has also increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.
The transformation of pharmaceutical companies is accelerating and forcing the upgrading of production equipment (photo source: Pharmaceutical Network) In addition to accelerating the transformation in research and development, pharmaceutical companies are also accelerating the upgrading of pharmaceutical production
.
It is reported that in recent years, many pharmaceutical companies are building new manufacturing bases in order to expand production and develop higher quality
.
For example, last year, Hongdou Group's anti-tumor high-end complex preparation smart factory project with a total investment of 520 million yuan has officially started
.
This project is an important manifestation of the Group's accelerated promotion of intelligent and high-end development, and is also a key project to enhance the company's international competitiveness
.
It is estimated that the annual output of anti-tumor injections will reach 20 million bottles, and the annual output of anti-tumor solid preparations will reach 100 million tablets, with an output value of more than 1.
5 billion yuan and an annual profit of 300 million yuan
.
In addition, Qilu Pharmaceutical also began to accelerate the construction of a high-end intelligent processing and manufacturing center project in the same year
.
It is understood that the project is expected to have a total investment of nearly 700 million yuan.
After completion, it is expected to become a domestic pharmaceutical production line with a high degree of automation and intelligence, helping pharmaceutical companies achieve stable production and overproduction, and improve production efficiency
.
It should be noted that the industry believes that due to factors such as the pharmaceutical industry and the accelerated transformation of pharmaceutical companies, the pharmaceutical equipment industry, which is closely related to pharmaceutical production, has also ushered in new opportunities for development.
marked change
.
In the past, the number of pharmaceutical equipment manufacturers in my country was small, the variety of pharmaceutical machines was small, and most of them mainly produced single equipment, relying on low-level repeated production. .
However, at present, more and more pharmaceutical machine companies have actively started the transformation, accelerating the development from the production of single equipment to the manufacture of diversified equipment.
While the product pipeline is becoming more and more abundant, they are also constantly meeting the new requirements of users
.
As far as the author understands, from an overall point of view, many current pharmaceutical equipment companies have integrated the core parts manufacturing process into product research and development, focusing on solving user manufacturing problems, meeting users' personalized needs in terms of intelligence, automation, environmental protection, etc.
, and in While releasing production capacity, it is committed to alleviating the rising cost pressure of users
.
Among them, it is obvious that with the continuous development of China's pharmaceutical industry and stricter drug quality supervision, the development of the pharmaceutical equipment industry towards intelligence has become a major trend
.
It is worth mentioning that, under the continuous efforts of domestic pharmaceutical machine companies, more and more results have been achieved
.
For example, an automatic production line built by a pharmaceutical machine company can realize automated, digital and intelligent production, and can be personalized and expanded according to user needs
.
The whole line has the function of remote diagnosis and maintenance, and can be integrated and connected with the workshop MES system to realize the digital management of the smart factory
.
There is also a smart medical equipment manufacturing project invested by a pharmaceutical machine company of 1 billion yuan.
At present, all three standardized production workshops have been completed, and the rest are progressing in an orderly manner, and it is planned to be completed in 2023
.
The project is aimed at the core areas of the health industry such as granulation line equipment, solid preparation equipment, etc.
After the project is put into operation, it can achieve an annual output of 4,000 sets of high-end pharmaceutical equipment, and the output value of the enterprise will increase by 5 times
.
Industry analysts believe that, judging from the current industry development trend, industrial transformation has become the general trend of the pharmaceutical industry
.
In this context, in addition to accelerating innovation, pharmaceutical equipment companies should also integrate research and development, talent, management and other aspects, and cut in from multiple perspectives to fight a "cooperation war" for the transformation and upgrading of the pharmaceutical industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Data shows that in recent years, the innovation and R&D investment of local pharmaceutical companies has continued to rise
.
Among them, the R&D investment of large-scale enterprises has an average annual growth rate of about 8%, and the R&D expenses of listed companies will account for more than 6% of sales revenue in 2020
.
In addition, the R&D investment of innovative drug industry chain companies in the third quarter of 2021 has also increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.
The transformation of pharmaceutical companies is accelerating and forcing the upgrading of production equipment (photo source: Pharmaceutical Network) In addition to accelerating the transformation in research and development, pharmaceutical companies are also accelerating the upgrading of pharmaceutical production
.
It is reported that in recent years, many pharmaceutical companies are building new manufacturing bases in order to expand production and develop higher quality
.
For example, last year, Hongdou Group's anti-tumor high-end complex preparation smart factory project with a total investment of 520 million yuan has officially started
.
This project is an important manifestation of the Group's accelerated promotion of intelligent and high-end development, and is also a key project to enhance the company's international competitiveness
.
It is estimated that the annual output of anti-tumor injections will reach 20 million bottles, and the annual output of anti-tumor solid preparations will reach 100 million tablets, with an output value of more than 1.
5 billion yuan and an annual profit of 300 million yuan
.
In addition, Qilu Pharmaceutical also began to accelerate the construction of a high-end intelligent processing and manufacturing center project in the same year
.
It is understood that the project is expected to have a total investment of nearly 700 million yuan.
After completion, it is expected to become a domestic pharmaceutical production line with a high degree of automation and intelligence, helping pharmaceutical companies achieve stable production and overproduction, and improve production efficiency
.
It should be noted that the industry believes that due to factors such as the pharmaceutical industry and the accelerated transformation of pharmaceutical companies, the pharmaceutical equipment industry, which is closely related to pharmaceutical production, has also ushered in new opportunities for development.
marked change
.
In the past, the number of pharmaceutical equipment manufacturers in my country was small, the variety of pharmaceutical machines was small, and most of them mainly produced single equipment, relying on low-level repeated production. .
However, at present, more and more pharmaceutical machine companies have actively started the transformation, accelerating the development from the production of single equipment to the manufacture of diversified equipment.
While the product pipeline is becoming more and more abundant, they are also constantly meeting the new requirements of users
.
As far as the author understands, from an overall point of view, many current pharmaceutical equipment companies have integrated the core parts manufacturing process into product research and development, focusing on solving user manufacturing problems, meeting users' personalized needs in terms of intelligence, automation, environmental protection, etc.
, and in While releasing production capacity, it is committed to alleviating the rising cost pressure of users
.
Among them, it is obvious that with the continuous development of China's pharmaceutical industry and stricter drug quality supervision, the development of the pharmaceutical equipment industry towards intelligence has become a major trend
.
It is worth mentioning that, under the continuous efforts of domestic pharmaceutical machine companies, more and more results have been achieved
.
For example, an automatic production line built by a pharmaceutical machine company can realize automated, digital and intelligent production, and can be personalized and expanded according to user needs
.
The whole line has the function of remote diagnosis and maintenance, and can be integrated and connected with the workshop MES system to realize the digital management of the smart factory
.
There is also a smart medical equipment manufacturing project invested by a pharmaceutical machine company of 1 billion yuan.
At present, all three standardized production workshops have been completed, and the rest are progressing in an orderly manner, and it is planned to be completed in 2023
.
The project is aimed at the core areas of the health industry such as granulation line equipment, solid preparation equipment, etc.
After the project is put into operation, it can achieve an annual output of 4,000 sets of high-end pharmaceutical equipment, and the output value of the enterprise will increase by 5 times
.
Industry analysts believe that, judging from the current industry development trend, industrial transformation has become the general trend of the pharmaceutical industry
.
In this context, in addition to accelerating innovation, pharmaceutical equipment companies should also integrate research and development, talent, management and other aspects, and cut in from multiple perspectives to fight a "cooperation war" for the transformation and upgrading of the pharmaceutical industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.